Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04266249
Title CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab + Trastuzumab

Paclitaxel + Pertuzumab + Trastuzumab

Ado-trastuzumab emtansine

Docetaxel + Pertuzumab + Trastuzumab

Nab-paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.